Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chunggei
Tokyo, Tokyo, Japan
- Ownership
- Private
- Employees
- ~7778
- Development stage
- Other
01
Overview
Chugai has successfully launched several novel biologics and antibodies (including Actemra/tocilizumab, Hemlibra, Enspryng/satralizumab, and contributed to Roche’s portfolio like Avastin, Tarceva, and Kadcyla)[6]. Multiple programs have Breakthrough Therapy Designation in the US. The pipeline comprises both in-house and Roche-partnered programs, stretching from preclinical to global commercial stages[1][4][6].
- Therapeutic areas
- ImmunologyRheumatologyHematologyOncologyNeurology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateSmall moleculeBiologicBispecific monoclonal antibodyMid-size molecule
- Industry
- Pharma
02
Partnerships
Beyond the preview
Go deeper on Chunggei.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chunggei.